scholarly journals The Association Between The Interval of Radioiodine Treatment and The Response and Adverse Effect in Patients with Non-Progressive Lung Metastases From Differentiated Thyroid Cancer

2021 ◽  
Author(s):  
Hongxi Wang ◽  
Rong Tian ◽  
Lei Shi ◽  
Rui Huang ◽  
Bin Liu
Keyword(s):  
Thyroid Cancer ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Lung Metastases ◽  
Radioiodine Treatment ◽  
Short Term ◽  
Change Rate ◽  
Response Interval ◽  
Significant Difference ◽  
Term Response

Abstract Purpose To assess the association between the interval of radioiodine treatment (RT) and short-term response and adverse effects in patients with non-progressive lung metastases from differentiated thyroid cancer (DTC).Methods A total of 147 neighboring RT course pairs from 78 patients with 131I-avid non-progressive lung metastases from DTC were retrospectively analyzed. The courses were categorized into two groups by interval of neighboring therapeutic 131-I administrations (≤12 months and >12 months). The short-term therapy response and adverse effects of the two groups were evaluated.Results No significant differences were found between the two groups in the change rate of thyroid stimulating hormone (TSH) stimulated serum thyroglobulin (ΔsTg%) (P=0.806) or the change rate of metastasis lesion long diameter (ΔLLD%) (P=0.246). In the subanalysis considering the number of treatments (3 and >3 times), no significant difference was found (P>0.05). No difference was found in biochemical response (interval ≤12m: P=0.325, interval >12m:P=0.456) or structural response (interval ≤12m: P=0.760, interval >12m: P=0.563) between the former and latter courses with regard to different intervals. No difference was found in adverse events between former and latter courses with regard to different intervals (P>0.05).Conclusions The interval of RTs is not associated with the short-term response or adverse effects in patients with non-progressive lung metastases from DTC. Appropriately prolonging the interval in specific patients seems to be feasible, and the interval of RT should be individually managed in clinical practice.

Does the radioactive iodine dose affect smell, taste sensation and nose function?

2021 ◽  
Vol 135 (1) ◽  
pp. 50-56
Author(s):  
B Tutar ◽  
T Özülker ◽  
G Berkiten ◽  
S Karaketir ◽  
M E Ekincioğlu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Adverse Effects ◽  
Dose Group ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
High Dose ◽  
Test Results ◽  
Radioactive Iodine Therapy ◽  
Significant Difference ◽  
Iodine Dose

AbstractObjectiveTo detect whether the adverse effects of post-operative radioactive iodine therapy following differentiated thyroid cancer on smell, taste and nasal functions were associated with radioactive iodine dose.MethodsFifty-one patients who had undergone total thyroidectomy because of differentiated thyroid cancer were divided into two groups depending on the post-operative radioactive iodine therapy dose: low dose group (50 mCi; 21 patients) and high dose group (100–150 mCi; 30 patients). The Sniffin’ Sticks smell test, the Taste Strips test and the 22-item Sino-Nasal Outcome Test were performed on all patients one week before therapy, and at two months and one year following therapy.ResultsStatistically significant differences were detected in the Sniffin’ Sticks test results, total odour scores, total taste scores and Sino-Nasal Outcome Test results between the assessment time points. There was no statistically significant difference between the low and high dose groups in terms of odour, taste or Sino-Nasal Outcome Test scores either before or after therapy.ConclusionRadioactive iodine therapy has some short- and long-term adverse effects on nasal functions and taste and odour sensations, which affect quality of life. These effects are not dose-dependent.

Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin

2018 ◽  
Vol 31 (7) ◽  
pp. 751-756 ◽  
Author(s):  
Lina Liu ◽  
Fang Huang ◽  
Bin Liu ◽  
Rui Huang
Keyword(s):  
Computed Tomography ◽  
Thyroid Cancer ◽  
Lymph Node ◽  
Distant Metastasis ◽  
Differentiated Thyroid Cancer ◽  
Lung Metastases ◽  
Whole Body ◽  
Emission Computed Tomography ◽  
Neck Lymph Node ◽  
Significant Difference

Abstract Background The present study was designed to determine the value of pre-ablation stimulated thyroglobulin (s-Tg) in predicting distant metastasis (DM) at the time of ablation in children with differentiated thyroid cancer. Methods From August 2009 to December 2016, consecutive children with differentiated thyroid cancer undergoing remnant ablation were retrospectively analyzed. Serum s-Tg was measured with the high-sensitive electrochemiluminescence immunoassay during hypothyroidism at ablation just before the ablative radioactive iodine (131I) administration. Post-ablation, whole body planar scintigraphy was obtained 5 days after administration of ablation activity of 131I. Single photon emission computed tomography/low-dose computed tomography (SPECT/CT) was added for children whose planar findings were inconclusive. Receiver-operating characteristics (ROC) curve analysis was employed to find a cut-off level of pre-ablation s-Tg as a predictor of DM at the time of ablation. Results Fifty-seven children were included for the analysis. Metastases were noticed on post-ablation scintigraphy in 20 (35%) children: five post-operative residual neck lymph node metastases, four post-operative residual neck lymph node and lung metastases, three mediastinal lymph node and lung metastases and eight lung metastases. A significant difference in pre-ablation s-Tg levels was found in children with DM compared with those without DM, 603.5 vs. 5.7 ng/mL, respectively. A pre-ablation s-Tg level of 156 ng/mL was established as the optimal cut-off point to predict DM. Conclusions This study demonstrated that pre-ablation s-Tg could potentially act as a predictor of DM at the time of ablation in children with differentiated thyroid cancer. We also propose a specific pre-ablation s-Tg cut-off value of 156 ng/mL as an optimal threshold for practical use.

scholarly journals Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Liyan Lu ◽  
Fengling Shan ◽  
Wenbin Li ◽  
Hankui Lu
Keyword(s):  
Thyroid Cancer ◽  
Side Effects ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Gastrointestinal Symptoms ◽  
Medical Intervention ◽  
Short Term ◽  
Remnant Ablation ◽  
Body Sensation ◽  
Node Metastases

Objectives. I-131 therapy for differentiated thyroid cancer (DTC) could induce adverse effects. The purpose of this study was to report and analyze symptoms after I-131 treatment within the hospitalization and present relevant medical intervention.Methods. I-131 doses ranging from 3.7 to 9.25 GBq (100–250 mCi) were administrated for thyroid remnant ablation or treating DTC metastases. 117 patients with DTC for I-131 therapy were monitored through the video and intercommunicating with standardized questionnaire at different time points after I-131 oral administration. Adverse effects were recorded and relevant clinical factors were analyzed.Results. Among all the 117 patients, 55 cases complained of neck’s pain or swelling and 79 cases presented with gastrointestinal symptoms. Pain or swelling of salivary gland occurred in 15 patients, headache and vertigo in 10, insomnia in 9, vocal cord paralysis in 6, fatigue or general malaise in 6, and foreign body sensation in 5. Body numbness and urinary symptoms were observed in only 1 case, respectively. Those side effects were related with sex, pre-I-131 treatment TSH levels, frequency of I-131 therapy, and lymph node metastases.Conclusions. Short-term side effects after I-131 therapy for DTC patients varied individually; severe symptoms were not uncommon but generally did not need emergent medical intervention.

Relationship between Thyroglobulin and Tumor Detectabilily with Thallium-201 in Differentiated Thyroid Cancer

2000 ◽  
Vol 39 (01) ◽  
pp. 10-15 ◽  
Author(s):  
S. P. Müller ◽  
Ch. Reiners ◽  
A. Bockisch ◽  
Katja Brandt-Mainz
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Roc Analysis ◽  
Tsh Suppression ◽  
Significant Difference ◽  
Test Specificity ◽  
The Relationship ◽  
Tumor Scintigraphy ◽  
Tsh Stimulation

Summary Aim: Tumor scintigraphy with 201-TICI is an established diagnostic method in the follow-up of differentiated thyroid cancer. We investigated the relationship between thyroglobulin (Tg) level and tumor detectability. Subject and methods: We analyzed the scans of 122 patients (66 patients with proven tumor). The patient population was divided into groups with Tg above (N = 33) and below (N = 33) 5 ng/ml under TSH suppression or above (N = 33) and below (N = 33) 50 ng/ml under TSH stimulation. Tumor detectability was compared by ROC-analysis (True-Positive-Fraction test, specificity 90%). Results: There was no significant difference (sensitivity 75% versus 64%; p = 0.55) for patients above and below 5 ng/ml under TSH suppression and a just significant difference (sensitivity 80% versus 58%; p = 0.04) for patients above and below 50 ng/ml under TSH stimulation. In 18 patients from our sample with tumor, Tg under TSH suppression was negative, but 201-TICI-scan was able to detect tumor in 12 patients. Conclusion: Our results demonstrate only a moderate dependence of tumor detectability on Tg level, probably without significant clinical relevance. Even in patients with slight Tg elevation 201-TICI scintigraphy is justified.

Short-Term Outcomes after Unilateral versus Complete Thyroidectomy for Malignancy: A National Perspective

2009 ◽  
Vol 75 (1) ◽  
pp. 20-24 ◽  
Author(s):  
Marc Zerey ◽  
Ajita S. Prabhu ◽  
William L. Newcomb ◽  
Amy E. Lincourt ◽  
Kent W. Kercher ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Length Of Stay ◽  
Differentiated Thyroid Cancer ◽  
Operative Management ◽  
National Inpatient Sample ◽  
Short Term ◽  
Thyroid Lobectomy ◽  
Well Differentiated ◽  
National Perspective ◽  
Total Charges

The extent of thyroidectomy for well-differentiated thyroid cancer (WDTC) remains controversial. We compared outcomes of patients undergoing unilateral thyroid lobectomy (UTL) versus complete thyroidectomy (CT) to determine the best operative management of WDTC. We compared outcomes of patients who underwent UTL or CT for malignancy using the 1999 to 2003 editions of the National Inpatient Sample database. A total of 13,854 patients underwent UTL (n = 4,238) and CT (n = 9,616). The CT group was more likely to have complications than the UTL group (15% vs 6%, P < 0.0001). Mean total charges were higher in the CT group ($11,432) versus the UTL group ($9,739), as was LOS (2 days versus 1 day); P < 0.0001. Complete thyroidectomy is associated with increased morbidity, total charges, and length of stay. The higher risk of short-term complications should be considered when considering performing a complete thyroidectomy for WDTC.

scholarly journals Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors

2015 ◽  
Vol 173 (3) ◽  
pp. 399-408 ◽  
Author(s):  
Hong-Jun Song ◽  
Zhong-Ling Qiu ◽  
Chen-Tian Shen ◽  
Wei-Jun Wei ◽  
Quan-Yong Luo
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Pulmonary Metastasis ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Pulmonary Metastases ◽  
Lung Metastases ◽  
Whole Body ◽  
Metastatic Node ◽  
Serum Thyroglobulin

ContextData from a large cohort of patients with pulmonary metastases from differentiated thyroid cancer (DTC) were retrospectively analyzed.ObjectiveTo assess the effect of radioiodine therapy and investigate the prognostic factors of survival for patients with pulmonary metastasis secondary to DTC.MethodsA total of 372 patients with pulmonary metastasis from DTC treated with131I entered the study. According to the results of131I whole-body scan (WBS), pulmonary metastases were classified as131I-avid and non-131I-avid. For patients with131I-avid lung metastases, treatment response was measured by three parameters: serum thyroglobulin (Tg) levels, chest computed tomography (CT) and post-therapeutic131I-WBS. Overall survival was calculated by the Kaplan–Meier method. Factors predictive of the outcome were determined by multivariate analyses.ResultsAmong patients demonstrating131I-avid pulmonary metastases (256/372, 68.8%), 156 cases (156/256, 60.9%) showed a significant decrease in serum Tg levels after131I therapy and 138 cases (138/229, 60.3%) showed a reduction in pulmonary metastases on follow-up CT. A complete cure, however, was only achieved in 62 cases (62/256, 24.2%). Multivariate analysis showed that only age, the presence of multiple distant metastases and pulmonary metastatic node size were significant independent variables between the groups of131I-avid and non-131I-avid.ConclusionThis study indicated that, most131I-avid pulmonary metastases from DTC can obtain partial or complete remission after131I therapy. Younger patients (<40 years old) with only pulmonary metastases and small (‘fine miliaric’ or micronodular) metastases appear to have relative favorite outcomes. Patients who do not respond to131I treatment have a worse prognosis.

Sign in / Sign up

Export Citation Format

Share Document